论文部分内容阅读
目的观察门冬胰岛素50治疗37例血糖控制不达标的2型糖尿病患者的临床疗效。方法选择37例经口服药治疗血糖不达标的2型糖尿病患者,给予门冬胰岛素50,3次/日,餐前注射,治疗12周,观察患者治疗前后空腹血糖(FPG)、餐后2小时血糖(2h PG)、糖化血红蛋白(Hb A1c)、体重指数(BMI)、低血糖发生情况等各项指标的变化,总结治疗效果。结果 37例空腹血糖、餐后2小时血糖控制水平有不同程度改善,Hb A1c水平降低,差异均有统计学意义(P<0.05)。低血糖发生率较低。结论门冬胰岛素50治疗2型糖尿病疗效显著,特别是对餐后血糖的控制效果突出,且安全性良好。
Objective To observe the clinical efficacy of insulin aspart 50 in 37 patients with type 2 diabetes who do not control their glycemic control. Methods 37 patients with type 2 diabetes mellitus who failed to meet the standard of glycemic control were enrolled in this study. Insulin asparts were administered 50,3 times a day for 12 weeks before and after treatment. The fasting blood glucose (FPG), fasting blood glucose (FPG) Blood glucose (2h PG), Hb A1c, body mass index (BMI), the occurrence of hypoglycemia and other indicators of change, to sum up the treatment effect. Results 37 cases of fasting blood glucose, 2 hours postprandial blood glucose levels have improved to varying degrees, Hb A1c levels decreased, the differences were statistically significant (P <0.05). Low incidence of hypoglycemia. Conclusion Aspart Insulin 50 treatment of type 2 diabetes significant effect, especially for postprandial blood glucose control effect is outstanding, and the safety is good.